血浆脂联素水平、PWV与冠心病的相关性研究
|
摘要
目的
探讨血浆脂联素水平、脉搏波速(PWV)在冠心病患者中的变化,以及二者与冠心病的临床分型、病变程度的关系,并探讨二者之间的关系及临床意义。
方法
本研究分冠脉组和对照组,65例冠心病患者均选自2009年6月-2011年6月期间本院心内科住院病人,对照组从2130位健康体检者筛选出且冠脉造影证实冠脉血管正常,无其他原因心血管疾病,无高血压及糖尿病,各项检测指标均在正常范围。采用酶联免疫法检测血浆脂联素的水平,动脉硬化检测仪检测PWV。分别根据冠心病临床分型、严重程度、PWV值进行分组,比较各组间的关系。
结果
.165例冠脉组和65例对照组,测得血浆脂联素水平,均数±标准差分别是6.26±2.01,9.39±2.56,两组差异有统计学意义(P<0.05)；
2.65例冠心病组,稳定型心绞痛有31例,占47.69%,血浆脂联素8.98±2.56,不稳定型心绞痛有24例,占36.92%血浆脂联素6.02±2.03,心肌梗死有10例,占15.38%,血浆脂联素4.56±1.99,每两组进行t检验,P均小于0.05,差异有统计学意义；
3.65例冠心病组,一支病变有21例,占32.30%,血浆脂联素7.98±2.16,二支病变有25例,占36.46%,血浆脂联素5.02±1.98,三支病变有19例,占29.23%,血浆脂联素3.56±2.33,如表3.3所示,每两组进行t检验,P均小于0.05,差异有统计学意义；
4.65例冠脉组和65例对照组,测得baPWV值分别是15.27±1.70m/s、12.34±2.50m/s,进行两独立样本的均数比较,P值<0.05,差异有统计学意义；
565例冠心病组,稳定型心绞痛有31例,占47.69%,baPWV值14.01±2.16,不稳定型心绞痛有24例,占36.92%baPWV值15.02±1.03,心肌梗死有10例,占15.38%,baPWV值15.56±1.39如表3.3所示,每两组进行t检验,P均大于0.05,差异无统计学意义。
6.65例冠心病组,一支病变有21例,占32.30%,baPWV值为13.78±2.26,二支病变有25例,占36.46%,baPWV值15.20±2.58,三支病变有19例,占29.23%,baPWV值17.46±2.43,每两组进行t检验,P均小于0.05,差异有统计学意义；
7.冠心病患者baPWV平均测定值为15.27±1.70,将测量值在14.00(m/s)以下的作为低baPWV组,14.00(m/s)以上的作为高baPWV组,其中低baPWV组36例,高baPWV组29例,比较低baPWV组和高baPWV血浆脂联素的水平,进行两独立样本的均数比较,P值<0.05,差异有统计学意义；
结论
1.血浆脂联素、PWV与冠心病有关,冠心病患者血浆脂联素水平较非冠心病患者低,PWV值较非冠心病患者高；
2.血浆脂联素水平与冠心病的临床类型以及病变程度有关,随着冠状动脉病变程度和范围的增加,血浆脂联素浓度逐渐下降,PWV与冠心病的病变程度有关,随着病变程度的加重而渐高；
3.冠心病患者PWV值越高,脂联素水平越低,二者有协调作用。
Objective
Explore plasma adiponectin, pulse wave velocity (PWV) changes in patients with coronary heart disease, further discussing both with coronary heart disease clinical classification of lesions and the degree of relationship, and to explore the relationship between them and clinical significance.
Methods
The study points coronary heart disease group and control group,65cases of coronary heart disease patients were selected from June2009-June2011during our heart medicine hospital patients, from2130healthy check-up in the control group were those with angiographically demonstrated coronary arteries and normal, no other causes of cardiovascular disease, hypertension, and diabetes without, the detection of the indexes in the normal range. The enzyme league immune method to detect the plasma adiponectin levels, arteriosclerosis detector PWV detection. According to the clinical classification of coronary heart disease, serious degree, PWV group value, this paper discusses the relations between the groups.
Results
165cases of coronary group and65cases of control group, the plasma adiponectin, x±s respectively is6.26±2.01,9.39±2.56, two groups was statistically significant difference (P<0.05);
265cases of coronary heart disease, stable angina with31patients (47.69%), plasma adiponectin8.98±2.56, unstable angina has24cases, accounting for36.92%of the plasma adiponectin6.02±2.03, myocardial infarction has10patients (15.38%), plasma adiponectin4.56±1.99, each two groups t test, P value were less than0.05, the difference was statistically significant;
365cases of coronary heart disease, coronary artery disease a21cases, accounting for32.30%, plasma adiponectin7.98±2.16, two artery disease25patients (36.46%), plasma adiponectin5.02±1.98, three teams of coronary artery disease (19cases),29.23%, plasma adiponectin3.56±2.33, each two groups t test, P value were less than0.05, the difference was statistically significant;
465cases of coronary group and65cases of control group, and baPWV value is measured respectively15.27±1.70m/s,12.34±2.50m/s, two independent sample mean more, P<0.05), and the value difference was statistically significant;
565cases of coronary heart disease, stable angina with31cases, accounting for47.69%, baPWV value14.01±2.16, unstable angina has24cases, accounting for36.92%of the value baPWV15.02±1.03, myocardial infarction has10cases, accounting for15.38%, baPWV value15.56±1.39such as table3.3shows, the two groups each t test, P value are greater than0.05, the difference was not statistically significant.
665cases of coronary heart disease, a coronary artery pathological changes of21cases, accounting for32.30%, baPWV value of13.78±2.26, two artery disease25cases, accounting for36.46%, baPWV value15.20±2.58, three teams of coronary artery disease (19cases),29.23%, baPWV value17.46±2.43, each two groups t test, P value were less than0.05, the difference was statistically significant;
7Patients with coronary heart disease baPWV average determination value of15.27±1.70, we provisions in14.00measured value (m/s) the following as low baPWV group,14.00(m/s) or more as a high baPWV group, with lower baPWV group of36cases, high baPWV group of29cases, low baPWV group and high baPWV plasma adiponectin leels are two independent sample mean more, P<0.05), and the value difference was statistically significant.
Conclusion
1Plasma adiponectin, PWV are associated to the coronary heart disease, coronary heart disease patients plasma adiponectin levels lower than those of the control group, PWV value coronary artery group the higher than those in the control group;
2Plasma adiponectin and coronary heart disease clinical types and levels are linked to the disease, coronary artery disease with the degree and range of aggravating, plasma adiponectin concentration also gradually reduced, there is a relationship between the coronary heart disease and PWV lesions degree, along with the pathological changes of the degree increased when the PWVD is increasing
3When PWV of the patients with coronary artery disease is increasing, but the plasma adiponectin levels drop, there is a coordinated role.
探讨血浆脂联素水平、脉搏波速(PWV)在冠心病患者中的变化,以及二者与冠心病的临床分型、病变程度的关系,并探讨二者之间的关系及临床意义。
方法
本研究分冠脉组和对照组,65例冠心病患者均选自2009年6月-2011年6月期间本院心内科住院病人,对照组从2130位健康体检者筛选出且冠脉造影证实冠脉血管正常,无其他原因心血管疾病,无高血压及糖尿病,各项检测指标均在正常范围。采用酶联免疫法检测血浆脂联素的水平,动脉硬化检测仪检测PWV。分别根据冠心病临床分型、严重程度、PWV值进行分组,比较各组间的关系。
结果
.165例冠脉组和65例对照组,测得血浆脂联素水平,均数±标准差分别是6.26±2.01,9.39±2.56,两组差异有统计学意义(P<0.05)；
2.65例冠心病组,稳定型心绞痛有31例,占47.69%,血浆脂联素8.98±2.56,不稳定型心绞痛有24例,占36.92%血浆脂联素6.02±2.03,心肌梗死有10例,占15.38%,血浆脂联素4.56±1.99,每两组进行t检验,P均小于0.05,差异有统计学意义；
3.65例冠心病组,一支病变有21例,占32.30%,血浆脂联素7.98±2.16,二支病变有25例,占36.46%,血浆脂联素5.02±1.98,三支病变有19例,占29.23%,血浆脂联素3.56±2.33,如表3.3所示,每两组进行t检验,P均小于0.05,差异有统计学意义；
4.65例冠脉组和65例对照组,测得baPWV值分别是15.27±1.70m/s、12.34±2.50m/s,进行两独立样本的均数比较,P值<0.05,差异有统计学意义；
565例冠心病组,稳定型心绞痛有31例,占47.69%,baPWV值14.01±2.16,不稳定型心绞痛有24例,占36.92%baPWV值15.02±1.03,心肌梗死有10例,占15.38%,baPWV值15.56±1.39如表3.3所示,每两组进行t检验,P均大于0.05,差异无统计学意义。
6.65例冠心病组,一支病变有21例,占32.30%,baPWV值为13.78±2.26,二支病变有25例,占36.46%,baPWV值15.20±2.58,三支病变有19例,占29.23%,baPWV值17.46±2.43,每两组进行t检验,P均小于0.05,差异有统计学意义；
7.冠心病患者baPWV平均测定值为15.27±1.70,将测量值在14.00(m/s)以下的作为低baPWV组,14.00(m/s)以上的作为高baPWV组,其中低baPWV组36例,高baPWV组29例,比较低baPWV组和高baPWV血浆脂联素的水平,进行两独立样本的均数比较,P值<0.05,差异有统计学意义；
结论
1.血浆脂联素、PWV与冠心病有关,冠心病患者血浆脂联素水平较非冠心病患者低,PWV值较非冠心病患者高；
2.血浆脂联素水平与冠心病的临床类型以及病变程度有关,随着冠状动脉病变程度和范围的增加,血浆脂联素浓度逐渐下降,PWV与冠心病的病变程度有关,随着病变程度的加重而渐高；
3.冠心病患者PWV值越高,脂联素水平越低,二者有协调作用。
Objective
Explore plasma adiponectin, pulse wave velocity (PWV) changes in patients with coronary heart disease, further discussing both with coronary heart disease clinical classification of lesions and the degree of relationship, and to explore the relationship between them and clinical significance.
Methods
The study points coronary heart disease group and control group,65cases of coronary heart disease patients were selected from June2009-June2011during our heart medicine hospital patients, from2130healthy check-up in the control group were those with angiographically demonstrated coronary arteries and normal, no other causes of cardiovascular disease, hypertension, and diabetes without, the detection of the indexes in the normal range. The enzyme league immune method to detect the plasma adiponectin levels, arteriosclerosis detector PWV detection. According to the clinical classification of coronary heart disease, serious degree, PWV group value, this paper discusses the relations between the groups.
Results
165cases of coronary group and65cases of control group, the plasma adiponectin, x±s respectively is6.26±2.01,9.39±2.56, two groups was statistically significant difference (P<0.05);
265cases of coronary heart disease, stable angina with31patients (47.69%), plasma adiponectin8.98±2.56, unstable angina has24cases, accounting for36.92%of the plasma adiponectin6.02±2.03, myocardial infarction has10patients (15.38%), plasma adiponectin4.56±1.99, each two groups t test, P value were less than0.05, the difference was statistically significant;
365cases of coronary heart disease, coronary artery disease a21cases, accounting for32.30%, plasma adiponectin7.98±2.16, two artery disease25patients (36.46%), plasma adiponectin5.02±1.98, three teams of coronary artery disease (19cases),29.23%, plasma adiponectin3.56±2.33, each two groups t test, P value were less than0.05, the difference was statistically significant;
465cases of coronary group and65cases of control group, and baPWV value is measured respectively15.27±1.70m/s,12.34±2.50m/s, two independent sample mean more, P<0.05), and the value difference was statistically significant;
565cases of coronary heart disease, stable angina with31cases, accounting for47.69%, baPWV value14.01±2.16, unstable angina has24cases, accounting for36.92%of the value baPWV15.02±1.03, myocardial infarction has10cases, accounting for15.38%, baPWV value15.56±1.39such as table3.3shows, the two groups each t test, P value are greater than0.05, the difference was not statistically significant.
665cases of coronary heart disease, a coronary artery pathological changes of21cases, accounting for32.30%, baPWV value of13.78±2.26, two artery disease25cases, accounting for36.46%, baPWV value15.20±2.58, three teams of coronary artery disease (19cases),29.23%, baPWV value17.46±2.43, each two groups t test, P value were less than0.05, the difference was statistically significant;
7Patients with coronary heart disease baPWV average determination value of15.27±1.70, we provisions in14.00measured value (m/s) the following as low baPWV group,14.00(m/s) or more as a high baPWV group, with lower baPWV group of36cases, high baPWV group of29cases, low baPWV group and high baPWV plasma adiponectin leels are two independent sample mean more, P<0.05), and the value difference was statistically significant.
Conclusion
1Plasma adiponectin, PWV are associated to the coronary heart disease, coronary heart disease patients plasma adiponectin levels lower than those of the control group, PWV value coronary artery group the higher than those in the control group;
2Plasma adiponectin and coronary heart disease clinical types and levels are linked to the disease, coronary artery disease with the degree and range of aggravating, plasma adiponectin concentration also gradually reduced, there is a relationship between the coronary heart disease and PWV lesions degree, along with the pathological changes of the degree increased when the PWVD is increasing
3When PWV of the patients with coronary artery disease is increasing, but the plasma adiponectin levels drop, there is a coordinated role.
引文
[1]胡大一.促进心血管健康实现心血管疾病预防战略前移[J].中华心血管病杂志,2010,38(4)：290-291.
[2]Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity [J]. Int J Inflam,2011,2011(376909.
[3]Yokota T Oritani K, Takahashi I, ct al. Adiponectin,a new member of the family of solubledefense collagens, negatively regulates the growth ofmyelomonocytic progenitors and the functions ofmacrophages[J]. Blood,2000,96:1723-1732.
[4]王现国,陈新忠,夏东升等.冠心病患者冠脉病变程度与心外膜脂肪脂联素表达的关系[J].中华实验外科杂志,2012,29(6)：1181-1183.
[5]焦路阳,王宇,袁宇等.冠心病患者血清内脂素和脂联素水平的变化及临床意义[J].检验医学,2012,27(5)：349-351,357.
[6]沈佳,陈芳,刘志军等.宁夏回族人群脂联素水平及基因单核苷酸多态性与冠心病相关性研究[J].中国全科医学,2012,15(11)：1222-1225.
[7]黄珊,彭文芳,蒋利等.脂联素在糖调节受损患者冠状动脉病变风险中的意义[J].中华内分泌代谢杂志,2012,28(12)：984-988.
[8]刘杰,李凌,陶海龙等.脂联素与冠脉临界病变斑块易损性的相关性分析[J].实用医学杂志,2012,28(8)：1293-1295.
[9]Arita Ykihara S, Ouchi N,et al. Adipocyte-daived plasmaprotein adiponeedn acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell[J]. Circulation.2002,105: 2893-2898.
[10]Okamoto Yarita, Nishida M, et al. An adipocyte-derived plasma protein,adiponectin,adheres to injuredvascular walls[J]. HormMetab Res.2000,32:47-50.
[11]Goksoy H, Dursunoglu D, Ozturk M, et al. The association between serum adiponectin levels and the severity of coronary artery lesions on the angiogram[J]. Turk Kardiyol Dern Ars,2009; 37(4):241-245.
[12]夏珂,郭兰燕,赵震宇等.合并糖代谢异常的冠心病患者血浆脂联素水平变化及其临床意义[J].中南大学学报(医学版),2012,37(2)：179-184.
[13]陈芳,武海亮,杨俏玲等.宁夏地区汉族代谢综合征患者脂联素基因多态性与冠心病的相关性研究[J].中国急救医学,2012,32(1)：24-29.
[14]张成秋,唐剑,胡和生等.急性冠脉综合征患者血浆脂联素和纤维蛋白原水平及其对冠脉病变程度的评价作用[J].中国老年学杂志,2012,32(20)：4512-4513.
[15]郝冬琴,韩文杰,刘恒亮等.急性冠脉综合征患者血清内脂素和脂联素水平分析[J].郑州大学学报(医学版),2012,47(3)：373-376.
[16]Wilson SR, Sabatine MS, Wiviott SD, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the pravastatin or atorvastatin evaluation and infection trial-thrombolysis in myocardial infarction 22 (prove it-timi 22) [J]. Am Heart J, 2011,161(6):1147-1155 e1141.
[17]Yamaji M, Tsutamoto T, Tanaka T, et al. Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus [J]. Circ J, 2009,73(12):2264-2269.
[18]Wang WH, Yu WH, Dong XQ, et al. Plasma adiponectin as an independent predictor of early death after acute intracerebral hemorrhage [J]. Clin Chim Acta, 2011,412(17-18):1626-1631.
[19]杨金凤.血清脂联素对冠心病冠状动脉病变评估的价值[J].浙江临床医学,2012,14(6)：729-730.
[20]王要鑫.脂联素与心血管疾病的研究现状与进展[J].重庆医学,2011,40(20)：2054-2056.
[21]马俊梅.冠心病患者血清脂联素水平及其影响因素分析[J].山东医药,2011,51(17)：73-74.
[22]龚玮琦,陈巍,葛剑力等.冠心病患者冠脉血运重建术后血清脂联素水平的变化[J].中国老年学杂志,2011,31(3)：382-383.
[23]周南南,卓晶明,王建春等.冠状动脉粥样硬化患者血浆瘦素、脂联素的水平变化及意义[J].山东医药,2011,51(37)：64-65.
[24]白晓梅.脂联素在冠状动脉粥样硬化性心脏病中的重要作用[J].心血管病学进展,2011,32(6)：846-849.
[25]魏晓丽.脂联素在冠心病中的重要作用[J].心血管病防治知识(下半月),2012,(7)：47-49.
[26]张勤军,陈明聪APN、CD62P、hs-CRP在冠心病病程发展中的作用[J].放射免疫学杂志,2011,24(5)：554-556.
[27]金静,彭道泉,龚浩等.血清脂肪细胞型脂肪酸结合蛋白及脂联素水平与冠心病的相关性[J].中华心血管病杂志,2010,38(8)：706-710.
[28]曹学敏,金道群,陈志强等.冠心病患者血清脂联素和高敏C-反应蛋白水平及相关性研究[J].河北医药,2011,33(14)：2154-2155.
[29]薛亚彬.冠心病伴胰岛素抵抗患者血清脂联素水平的研究[J].中国医药指南,2012,10(15)：542-542.
[30]姜文兵,赵玮,张东矗等.血清脂联素水平与冠心病严重程度的相关性分析[J].中国医师进修杂志,2011,34(22)：3-6.
[31]牛新艳.血清脂联素水平及踝臂指数与冠状动脉病变程度的相关性研究[J].实用心脑肺血管病杂志,2012,20(3)：422-423.
[32]林鸿.脂联素与冠状动脉粥样硬化性心脏病临床研究进展[J].医学综述,2012,18(3)：354-356.
[33]孙卫平,吴永全,李觉等.脉搏波传导速度与冠心病心功能不全的相关性[J].中华内科杂志,2008,47(5)：382-384.
[34]贾新未,魏盟,陆志刚等.脉搏波传导速度对冠心病的诊断价值[J].诊断学理论与实践,2006,5(4)：332-335.
[35]王彦隆,闫旭龙,王增帅等.脉搏波速度、颈动脉内中膜厚度对冠状动脉粥样硬化预测价值及联合应用的意义[J].临床心血管病杂志,2010,26(12)：952-954.
[36]陈然,黄红光,戴海鹰等.冠心病患者血清脂联素水平的检测及意义[J].中国医师杂志,2010,12(11)：1548-1550.
[37]梁文生,蒋卫红.急性冠状动脉综合征患者血清脂联素和踝臂指数的变化及其相关性的研究[J].中国心血管杂志,2011,16(3)：189-191.
[38]朱文磊.探讨脂联素与冠心病危险因素的关系[J].四川医学,2010,31(10)：1546-1549.
[39]黄祥征,潘超英.检测冠心病患者APN和hs-CRP水平的临床意义[J].右江民族医学院学报,2011,33(5)：626-627.
[40]刘健,李群芳,吴洁等.脂联素对冠心病患者的保护作用研究进展[J].中国医药指南,2011,09(24)：6,10.
[41]黄祥征,潘超英.血浆脂联素检测在冠心病患者中的临床应用价值[J].齐齐哈尔医学院学报,2011,32(10)：1620.
[42]Dridi S, Taouis M. Adiponectin and energy homeostasis:Consensus and controversy [J]. J Nutr Biochem,2009,20(11):831-839.
[43]Matatda M, Shimomura I'Sara M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis[J]. J Biol Chem.2002,277: 37487-37491.
[44]Yokota T Oritani KTakahashi I et al. Adiponectin,a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of maerophages[J]. Blood.2000,96:1723-1732.
[45]张晓云,魏芳婧,徐力等.APN MMP-9hs-CRP在冠心病老年患者中的表达及临床意义[J].内蒙古医学杂志,2011,43(5)：513-516.
[46]李金怀,韩斌,杨文东等.冠心病患者血清脂联素和P-选择素水平变化及其检测价值[J].临床医学,2011,31(4)：99-100.
[47]臧传欣,贾永平,吕吉元等.冠心病患者测定血清脂联素的临床意义及相关性研究[J].中西医结合心脑血管病杂志,2010,8(4)：403-404.
[48]王琳.冠心病患者血清脂联素及抵抗素变化的分析[J].中国实用医药,2012,07(8)：108-110.
[49]王彦青,张丽英,高铭枢等.急性冠脉综合征患者血浆脂联素水平分析[J].中西医结合心脑血管病杂志,2011,09(11)：1380.
[50]刘雅娟,武海亮,杨锐英等.脂联素与冠心病类型和心血管危险因素的关系[J].临床心血管病杂志,2010,26(1)：11-14.
[51]齐杰,韩清华,马锋等.PWV、ABI、IMT与冠心病冠脉狭窄程度的相关性分析[J].中西医结合心脑血管病杂志,2010,8(2)：161-162.
[52]牟春霞,安毅,魏梅等.血尿酸、PWV和ABI与冠心病的关系[J].青岛大学医学院学报,2010,46(4)：309-311.
[53]贾新未,魏盟,陆志刚等.主动脉脉搏波传导速度升高与冠心病发病的相关性[J].临床心血管病杂志,2007,23(12)：910-912.
[54]赵旭燕,刘惠亮,马春梅等.冠心病患者高敏C反应蛋白和脉搏波传导速度检测的意义[J].心血管康复医学杂志,2010,19(3)：239-241.
[55]朱淑贤,钱菊英,葛均波等.大动脉僵硬度与冠心病相关性研究[J].中华老年医学杂志,2007,26(1)：9-12.
[56]孙军昌,安毅.冠心病病人脉搏波传导速度和踝臂指数变化及意义[J].齐鲁医学杂志,2009,24(3)：251-252,255.
[57]王文忠,陈瑜容.血清脂联素水平、动脉脉搏波传导速度与冠心病的相关性研究[J].临床内科杂志,2012,29(10)：705-706.
[58]Brochu-Gaudreau K, Rehfeldt C, Blouin R, et al. Adiponectin action from head to toe[J]. Endocrine,2010,37(1):11-32.
[59]Ambrosi P, Oddoze C, Habib G. Plasma adiponectin:Risk factor or risk marker for arterial stiffness? [J]. Am J Cardiol,2009,104(5):742.
[60]Bik W, Baranowska B. Adiponectin-a predictor of higher mortality in cardiovascular disease or a factor contributing to longer life? [J]. Neuro Endocrinol Lett, 2009,30(2):180-184.
[61]马聪,刘惠亮,王晓辉等.大动脉弹性与冠状动脉病变严重程度关系探讨[J].中国误诊学杂志,2008,8(23)：5545-5547.
[62]孟晓敏,王鸿懿,喜杨等.内源分泌型高级糖基化终末产物受体与冠心病危险因素对动脉弹性的影响[J].中华老年心脑血管病杂志,2010,12(9)：813-816.
[63]李更新,杨玉恒,马秀华等.老年缺血性心脑血管疾病患者PWV及ABI的差异比较[J].中国老年学杂志,2010,30(21)：3078-3079.
[64]王延风,常志文,梁杰等.大动脉弹性与冠状动脉粥样硬化严重程度的关系[J].中国综合临床,2007,23(3)：195-197.
[65]白宏兴,李小平,武治东等.脉搏波传导速度和踝臂指数与冠心病的关系[J].陕西医学杂志,2009,38(11)：1483-1484.
[66]贾新未,魏盟,陆志刚等.脉搏波传导速度在冠心病诊断中的应用价值[J].临床心血管病杂志,2007,23(7)：513-515.
[67]杜娟,姜少燕,李健等.急性冠脉综合征患者血浆IL-17、hs-CRP及PWV的变化及意义[J].山东医药,2010,50(33)：49-50.
[68]范中杰,程康安,张抒扬等.冠心病患者脉搏波流速的研究[J].中国心血管病研究杂志,2006,4(10)：726-729.
[69]刘伯芹,安毅,曹广智等.血浆脂联素水平与冠脉病变及PWV、ABI的关系研究[J].心脑血管病防治,2009,9(1)：6-8.
[70]Feener EP,King GL. Vascular dysfunction in diabetes mellitus[J]. Lancet,1997; 350(suppl): S13-S19.
[71]Y Ouehi, K Terashita,T Nakamura,et al. Aortic pulse wave velocity in patients with coronary atherosclerosis-a comparison with coronary angiographie findings. Nippon Ronen Igakkai Zasshi, January 1,1991; 28(1):40-45.
[72]李佳月,赵玉生,侯允天等.脉搏波传导速度与冠状动脉病变严重程度的相关性：324例老年病例分析[J].中华老年多器官疾病杂志,2012,11(5)：360-363.
[73]拓胜军,白宏兴,梁延宏等.脉搏波传导速度与冠状动脉病变程度的相关性研究[J].心血管康复医学杂志,2010,19(4)：439-441.
[74]李厚荣,杜国伟,殷波等.208例脉搏波速度与冠状动脉粥样硬化的临床分析[J].医学综述,2012,18(3)：451-454.
[75]王彦江,高明明,张麟等.脉搏波速度与冠状动脉病变严重程度的相关性研究[J].首都医科大学学报,2010,31(6)：799-802.
[76]龚武田,李家富,罗廷福等.脉搏波速与冠状动脉炎症状态的关系研究[J].实用心脑肺血管病杂志,2011,19(11)：1840-1842.
[77]陆兆华.冠心病及其高危因素人群脉搏波传导速度监测研究[J].安徽医学,2012,33(3)：312-313.
[78]曾玉玲,刘婷.脉搏波传导速度对冠心病的预测价值研究[J].临床合理用药杂志,2012,05(3)：15.
[79]彭玲湘,范咏梅.冠心病患者脉搏波速和踝臂指数检测的临床意义探讨[J].中国民康医学,2011,23(14)：1723-1724.
[80]范文茂,徐新,胡秀莲等.冠心病患者脉搏波传导速度与血浆脑钠肽水平的相关性研究[J].中国现代药物应用,2010,04(16)：38-39.
[81]甘辉.脉搏波传导速度、踝臂指数、血尿酸对冠心病的预测价值[J].浙江临床医学,2012,14(2)：190-192.
[82]王小荣,孙彦琴,贾耀文等.大动脉功能测定与冠状动脉粥样硬化病变相关性分析[J].中国现代医生,2008,46(22)：66-67.
[83]于安忠,李智,高绍喜等.脉搏波传导速度与冠状动脉粥样硬化的相关性研究[J].山东医药,2009,49(9)：48-49.
[84]Ouchi N, Kihara S, Adta Y et al. Adiponectin, an adipocyte-derived plasma protein. Inhibits endothelial NF-KB signaling through a cAMP-dependent pathway[J]. Circulation,2000,102:1296.
[85]刘晓方.PWV和ABI的测定在冠状动脉粥样硬化检测中的应用[J].宁夏医学杂志,2007,29(4)：379-382.
[86]蔡凯愉,张维忠,邱惠丽等.影响动脉弹性功能的临床因素分析[J].中华心血管病杂志,2007,35(3)：234-237.
[87]张明华,叶平,骆雷鸣等.健康人不同部位脉搏波传导速度、反射波增强指数之间的相关性及影响因素[J].中华心血管病杂志,2010,38(11):998-1005.
[88]谭静,华琦,闻静等.高血压病患者脉搏波速度与心血管疾病危险因素[J].中华高血压杂 志,2007,15(10)：807-811.
[89]曾靖,程李涛,唐利军等.增强指数评估动脉僵硬度不如脉搏波速度敏感[J].中国动脉硬化杂志,2008,16(1)：43-46.
[90]曲娜,刘晓方,王淑霞.脉搏波速度与冠状动脉粥样硬化的关系[J].中国动脉硬化杂志,2007,15(3)：217-220.
[91]El Khatib N, Genieys S, Kazmierczak B, et al. Reaction-diffusion model of atherosclerosis development[J]. J Math Biol,2011.
[92]Badheka AO, Rathod AD, Bharadwaj AS, et al. Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease [J]. Angiology, 2011,62(6):473-479.
[93]Campbell DJ, Somaratne JB, Jenkins AJ, et al. Differences in myocardial structure and coronary microvasculature between men and women with coronary artery disease[J]. Hypertension,2011,57(2):186-192.
[94]Cote M, Cartier A, Reuwer AQ, et al. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the epic-norfolk prospective population study) [J]. Am J Cardiol,2011,108(3):367-373.
[95]Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease[J]. Heart,2004; 90(5):528-533
[96]冯笑梅,冀虎岗.冠心病患者血浆脂联素水平变化的探讨[J].江西医学检验,2006；24(5)：388-389.
[97]Vaiopoulos AG, Marinou K, Christodoulides C, et al. The role of adiponectin in human vascular physiology [J]. Int J Cardiol,2011.
[98]Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies[J]. Hypertension,1995,26:485-490.
[99]Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement[J]. Hypertens Res,2002,25:359-364.
[100]Hisayo yokoyama, Tetsuo Shoji, Eiji Kimoto, et al. Pulse Wave Velocity in Lower-Limb Arteries among Diabetic Patientes with Peripheral Arterial Disease. J Atheroscler Thromb.2003; 10:253-258
[101]Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ankle pulse wave velocity:all index of central arterial stiffness?[J]. J Hum Hypertens,2005,19:401-406
[102]王宏宇,张维忠,龚兰生,等.高血压合并动脉粥样硬化与大动脉缓冲功能的研究[J].中华心血管病杂志,2000,29：206-209.
[103]Blacher J,Asmar R,Djane S, et, al. Aortic pulse wave velocity fits a marker of cardiovascularrisk in hypertension patiens[J], Hypertension.1999; 33:1111-1117.
[104]Sutton-Tyrrel K,Newman A, Eleanor M, et al. Aortic sjiffness is associated with visceral adiposity in older adults enrolled in the study of Health,Agoing, and Body Composition[J]. Hypertension,2001; 38:429-433.
[105]郭兰燕,夏珂,程晋芳等.冠心病伴糖代谢异常患者血浆脂联素和Apelin的水平及临床意义[J].临床心血管病杂志,2011,27(10)：732-735.
[1]Yamaucki T,KamoN J, et al. globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis[J].Biol-Chem,2003,278:2461-2468.
[2]Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C 1 q, produced exclusively in akipocytes[J].Biol Chem,1995,270(45):26746-26749.
[3]张静,牛凡.血清瘦素、脂联素与冠心病病变程度的相关性研究[J].中西医结合心脑血管病杂志,2012,10(7)：783-784.
[4]王文忠,陈瑜容.血清脂联素水平、动脉脉搏波传导速度与冠心病的相关性研究[J].临床内科杂志,2012,29(10)：705-706.
[5]邓琳,李树壮.脂联素对冠心病的保护作用及其机制[J].大连医科大学学报,2012,34(3)：297-300.
[6]盛延文,王玉梅,梁菊萍等.冠状动脉粥样硬化病变患者血清脂联素的表达及临床价值[J].中国老年学杂志,2011,31(17)：3272-3273.
[7]Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity [J]. Nat Med,2001,7(8):941-946.
[8]Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects [J]. Nature,2003,423(6941):762-769.
[9]熊鹏锋,涂燕平.脉搏波传导速度与冠心病关系的研究进展[J].中国老年学杂志,2011,31(12)：2380-2382.
[10]陈希伟,韦建瑞,罗景云等.脉搏波传导速度在心血管病的应用进展[J].国际医药卫生导报,2011,17(7)：888-891.
[11]Guo XH, Wu LL, Li L. [progress in signal pathways involved in glucose and lipid metabolism induced by adiponectin] [J]. Sheng Li Ke Xue Jin Zhan,2010,41(6):471-474.
[12]Chinetfi G Zawadski C, Fmchart JC, et al. Expression of adiponectin receptors in human macrophages and regulation by agonists ofthe nuclear receptors PPAR alpha, PPAR gamma,and LXR[J]. Biochem Biophys Res Commun,2004,314:151.
[13]郝燕婷,张永珍,毛节明等.脉搏波速度与冠状动脉血流速度储备的相关性[J].中华医学杂志,2012,92(10)：685-688.
[14]耿国英,李凌,韩文杰等.冠心病合并糖尿病患者脉搏波传导速度的变化[J].中国医药指南,2012,10(2)：22-24.
[15]孙洪勇,黄健,李莉等.高血压病合并冠心病与大动脉脉搏波速度的关系[J].贵阳医学院学报,2008,33(4)：392-393.
[16]Hattori Y.Suzuki M.Hattori S, et al. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells[J].Diabetologia.2003,46(5):1543-1549.
[17]Chen H.Montagnani M.Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells [J]. JBiol Chem.2003,278(7):45021-45026.
[18]Ouchi N.Kihara S.Funahasi T, et al.Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.Circulation,2003,107(3):671-674.
[19]Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin act as an endogenous antithrombotic factor[J]. Arterioscl Thromb Vasc Biol,2006,26(1):224-230.
[20]韩文杰,刘恒亮,刘洋等.短期降糖治疗对冠心病并糖尿病患者脉搏波传导速度的影响[J].河南医学研究,2012,21(3)：299-301.
[21]刘晓芳,黄建英,张胜利等.冠心病患者血清脂联素水平与高敏C反应蛋白和胰岛素抵抗的关系[J].国际检验医学杂志,2013,34(2)：149-150.
[22]卢世明,刘占英,孙爱叶等.2型糖尿病合并冠心病患者脂联素测定及其意义[J].中国医学创新,2011,08(25)：5-8.
[23]黄祥征,潘超英.血浆脂联素检测在冠心病患者中的临床应用价值[J].齐齐哈尔医学院学报,2011,32(10)：1620.
[24]Maeda N.Shimomura l.Kishida K,el al. Diet-induced insulin resistance in micelaclcing adiponectin/ACRP30[J].Nat Med,2002,8(5):2654-2660.
[25]Julius S. Kjeldsen SE.Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial[J].Lancet.2004,363:2022-2031
[26]Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women[J]. Eur J Endoerinol,2002, 147:173-180.
[27]蔡静,李洁琪.不同病因房颤患者血浆脂联素与B型利钠肽前体及心功能的关系[J].山东医药,2012,52(37)：17-19.
[28]张宁汝,张恒,王本芳等.脂联素与冠心病临床相关性研究[J].中华全科医学,2012,10(5)：688-689.
[29]张宁汝,李妙男,张恒等.APN与冠脉病变程度相关性研究[J].中华全科医学,2012,10(8)：1194-1196.
[30]潘桂林,XU Da-hua,高潮等.脂联素：心血管疾病新的危险预测因子[J].心血管病学进展,2008,29(4)：628-632.
[31]王彦青,张丽英,高铭枢等.急性冠脉综合征患者血浆脂联素水平分析[J].中西医结合心脑血管病杂志,2011,09(11)：1380.
[32]Hotta K, Funahashi T, Bodkin NL, et al. Circulating concent rations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys[J]. Diabetes,2001,50(5):1126.
[33]Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal for mation[J]. J Biol Chem,2002,227(29):25863.
[34]雷娟,周淑娴,薛声能等.血清脂联素水平与冠脉病变严重程度的关系[J].中国医师杂志,2008,10(2)：195-197.
[35]耿银东,牟春平,赵晓辉等.脂联素和糖化血红蛋白与冠脉病变程度的相关性[J].心血管康复医学杂志,2010,19(2)：140-143.
[36]刘伯芹,安毅,曹广智等.血浆脂联素水平与冠脉病变及ABI的关系研究[J].心脑 血管病防治,2009,9(1)：6-8.
[37]Maeda N, Takahashi M, Funahashi T, et al. PPAR γ ligands increase express and plasma concentrations of adiponeetill, an adipose-derived protein[J]. Diabetes,2001,50:2094.
[38]Yu J GJavorschi S, Hevener AL, et al. The effect ofthiazolidinedione on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects[J]. Diabetes,2002, 51:2968-2974.
[39]李小平,杨成悌,张灵,等.高血压病患者血清脂联素水平的研究[J].中华心血管病杂志,2004,32(7)：596-599.
[40]邵明柏,冷吉燕,崔倩卫.老年高血压伴肥胖患者血清脂联素水平的变化及其临床意义[J].中国老年学杂志,2010,30(18)：2582-2584.
[41]周淑娴,雷娟,张玉玲,等.高血压患者胰岛素抵抗与血清脂联素及炎症标志物水平[J].中华高血压杂志,2008,16(2)：166-170.
[42]Admaczak M, Wiecek A, FullahaShi T, et al, challges plasma adiponectin concentration In patients with essentid hypertens[J], Am J HyperteIns,2003,16(1):72
[43]furuhashi M, Ura N, Higashiura K, et al, Blockade ofthe reInin angiotensin system increases adiponectin concertration in patients with essential hypertension[J], Hypertensio 2003.42:76-81.
[44]Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin:more than just another fat cell hormone?[J].Diabetes Care,2003,26(8):2442-2450.
[45]焦路阳,袁彬,袁晓梅等.血清内脂素、脂联素和C-反应蛋白与冠状动脉病变的相关性[J].新乡医学院学报,2012,29(8)：600-602.
[46]牛新艳.血清脂联素、血清淀粉样蛋白A与冠状动脉病变的相关性研究[J].中国全科医学,2011,14(28)：3232-3234.
[47]Fruebis j, Tsao TS, Javorschi S, et al.Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in Hlusele and caoses weight loss in mice[J]. Proc Natl Acad Sci USA,2001,98(4):2005-2010.
[48]Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis[J]. J Biol Chem,2002,277:37487
[49]刘蕴玲,阴东亮,刘好田,等.肥胖儿童血清脂联素水平与代谢综合征、早期动脉粥样硬化的相关性研究[J].中华内分泌代谢杂志,2010,26(9)：749-753.
[50]李筱雯,艾华,张宝慧,等.肥胖者或超重者血脂联素和心血管危险因素在减体重后的变化[J].中国康复医学杂志,2006,21(2)：132-135.
[51]Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. NatMed,2002,8(7):731.737.
[52]Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk [J]. Curr Med Chem,2010,17(36):4511-4520.
[53]Dagli N, Ozturk U, Karaca I, et al. Adiponectin levels in coronary artery ectasia [J]. Heart Vessels,2009,24(2):84-89.
[54]魏红霞,张葵,李雷等.血清脂联素与载脂蛋白A5及2型糖尿病的关系[J].现代生物医学进展,2012,12(8)：1498-1501.
[55]李晓燕,王铁成,刘世雷等.血清脂联素水平与冠状动脉病变程度的关系[J].中国血液流变学杂志,2009,19(3)：387-389.
[56]束振华.血清vWF及APN的检测与冠心病的关系及其临床意义[J].现代诊断与治疗,2011,22(3)：129-131.
[57].Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis and thrombosis [J]. Clin Appl Thromb Hemost,2006,12(2):163-168.
[58]Nalcamura Y,Shimada K,Fukuda D, et al.Implications of plasma con2centrations of adiponectin in patients with coronary artery disease [J].Heart (British Cardiac Society),2004,90 (5):528-533.
[59]杨金凤.血清脂联素对冠心病冠状动脉病变评估的价值[J].浙江临床医学,2012,14(6)：729-730.
[60]李晓红,卢伟智,刘怀昌等.代谢综合征对冠心病患者脂类代谢及炎症因子的影响[J].海南医学,2010,21(14)：53-54,67.
[61]张勤军,陈明聪.APN. CD62P, hs-CRP在冠心病病程发展中的作用[J].放射免疫学杂志,2011,24(5)：554-556.
[62]宋高峰,杨文东.2型糖尿病合并冠心病与脂联素及炎性因子的相关性[J].航空航天医学杂志,2011,22(8)：961-962.
[63]Kumada M,Kihara S,Ouchi N, et al.Adiponectin specifically increasedtissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macropages[J]Circulation 2004,109(17):2046-2049.
[64]Iacobellis G, Pistilli D, Gucciardo M, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease [J]. Cytokine, 2005,29(6):251-255.
[65]牛新艳.血清脂联素水平及踝臂指数与冠状动脉病变程度的相关性研究[J].实用心脑肺血管病杂志,2012,20(3)：422-423.
[66]李金怀,韩斌,杨文东等.冠心病患者血清脂联素和P-选择素水平变化及其检测价值[J].临床医学,2011,31(4)：99-100.
[67]王小凤,王毅,杨建国等.血清脂联素水平与高血压肥胖患者胰岛素抵抗的关系[J].中国老年学杂志,2013,33(1)：183-185.
[68]Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk [J]. Curr Med Chem,2010,17(36):4511-4520.
[69]Kobalava Zh D, Villeval'de SV, Isikova Kh V. [the role of adiponectin in development and progression of cardiovascular diseases] [J]. Kardiologiia,2009,49(1):51-58.
[70]Koz C, Uzun M, Yokusoglu M, et al. Evaluation of plasma adiponectin levels in young men with coronary artery disease [J]. Acta Cardiol,2007,62(3):239-243.
[71]Kizer JR, Benkeser D, Arnold AM, et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults [J]. J Clin Endocrinol Metab, 2013,98(1):255-263.
[72]Kanhai DA, Kranendonk ME, Uiterwaal CS, et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies [J]. Obes Rev, 2013.
[73]Zhang BC, Li WM, Xu YW. A meta-analysis of the association of adiponectin gene polymorphisms with coronary heart disease in chinese han population [J]. Clin Endocrinol (Oxf),2012,76(3):358-364.
[74]Xia K, Guo L, Zhao Z, et al. [plasma level of adiponectin in coronary heart disease patients combined with abnormal glucose metabolism] [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2012,37(2):179-184.
[75]EI-Mesallamy HO, Hamdy NM, Salman TM, et al. Adiponectin and se-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease [J]. Angiology,2012,63(2):96-102.
[76]Baldasseroni S, Mannucci E, Orso F, et al. Adiponectin in outpatients with coronary artery disease:Independent predictors and relationship with heart failure [J]. Nutr Metab Cardiovasc Dis,2012,22(3):292-299.
[77]Zhou NN, Zhuo JM, Wang JC, et al. [correlation of adiponectin gene snp+45t/g polymorphism and premature coronary heart disease of han ethnic males] [J]. Zhonghua Yi Xue Za Zhi, 2011,91(48):3413-3416.
[78]Prior SL, Jones DA, Gill GV, et al. Association of the adiponectin rs266729 c>g variant and coronary heart disease in the low risk'golden years'type 1 diabetes cohort [J]. Diabetes Res Clin Pract,2011,91(3):e71-74.
[79]Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women [J]. Atherosclerosis,2011,219(1):322-329.
[80]Parul SS, Mazumder M, Debnath BC, et al. Serum adiponectin in patients with coronary heart disease [J]. Mymensingh Med J,2011,20(1):78-82.
[2]Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity [J]. Int J Inflam,2011,2011(376909.
[3]Yokota T Oritani K, Takahashi I, ct al. Adiponectin,a new member of the family of solubledefense collagens, negatively regulates the growth ofmyelomonocytic progenitors and the functions ofmacrophages[J]. Blood,2000,96:1723-1732.
[4]王现国,陈新忠,夏东升等.冠心病患者冠脉病变程度与心外膜脂肪脂联素表达的关系[J].中华实验外科杂志,2012,29(6)：1181-1183.
[5]焦路阳,王宇,袁宇等.冠心病患者血清内脂素和脂联素水平的变化及临床意义[J].检验医学,2012,27(5)：349-351,357.
[6]沈佳,陈芳,刘志军等.宁夏回族人群脂联素水平及基因单核苷酸多态性与冠心病相关性研究[J].中国全科医学,2012,15(11)：1222-1225.
[7]黄珊,彭文芳,蒋利等.脂联素在糖调节受损患者冠状动脉病变风险中的意义[J].中华内分泌代谢杂志,2012,28(12)：984-988.
[8]刘杰,李凌,陶海龙等.脂联素与冠脉临界病变斑块易损性的相关性分析[J].实用医学杂志,2012,28(8)：1293-1295.
[9]Arita Ykihara S, Ouchi N,et al. Adipocyte-daived plasmaprotein adiponeedn acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell[J]. Circulation.2002,105: 2893-2898.
[10]Okamoto Yarita, Nishida M, et al. An adipocyte-derived plasma protein,adiponectin,adheres to injuredvascular walls[J]. HormMetab Res.2000,32:47-50.
[11]Goksoy H, Dursunoglu D, Ozturk M, et al. The association between serum adiponectin levels and the severity of coronary artery lesions on the angiogram[J]. Turk Kardiyol Dern Ars,2009; 37(4):241-245.
[12]夏珂,郭兰燕,赵震宇等.合并糖代谢异常的冠心病患者血浆脂联素水平变化及其临床意义[J].中南大学学报(医学版),2012,37(2)：179-184.
[13]陈芳,武海亮,杨俏玲等.宁夏地区汉族代谢综合征患者脂联素基因多态性与冠心病的相关性研究[J].中国急救医学,2012,32(1)：24-29.
[14]张成秋,唐剑,胡和生等.急性冠脉综合征患者血浆脂联素和纤维蛋白原水平及其对冠脉病变程度的评价作用[J].中国老年学杂志,2012,32(20)：4512-4513.
[15]郝冬琴,韩文杰,刘恒亮等.急性冠脉综合征患者血清内脂素和脂联素水平分析[J].郑州大学学报(医学版),2012,47(3)：373-376.
[16]Wilson SR, Sabatine MS, Wiviott SD, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the pravastatin or atorvastatin evaluation and infection trial-thrombolysis in myocardial infarction 22 (prove it-timi 22) [J]. Am Heart J, 2011,161(6):1147-1155 e1141.
[17]Yamaji M, Tsutamoto T, Tanaka T, et al. Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus [J]. Circ J, 2009,73(12):2264-2269.
[18]Wang WH, Yu WH, Dong XQ, et al. Plasma adiponectin as an independent predictor of early death after acute intracerebral hemorrhage [J]. Clin Chim Acta, 2011,412(17-18):1626-1631.
[19]杨金凤.血清脂联素对冠心病冠状动脉病变评估的价值[J].浙江临床医学,2012,14(6)：729-730.
[20]王要鑫.脂联素与心血管疾病的研究现状与进展[J].重庆医学,2011,40(20)：2054-2056.
[21]马俊梅.冠心病患者血清脂联素水平及其影响因素分析[J].山东医药,2011,51(17)：73-74.
[22]龚玮琦,陈巍,葛剑力等.冠心病患者冠脉血运重建术后血清脂联素水平的变化[J].中国老年学杂志,2011,31(3)：382-383.
[23]周南南,卓晶明,王建春等.冠状动脉粥样硬化患者血浆瘦素、脂联素的水平变化及意义[J].山东医药,2011,51(37)：64-65.
[24]白晓梅.脂联素在冠状动脉粥样硬化性心脏病中的重要作用[J].心血管病学进展,2011,32(6)：846-849.
[25]魏晓丽.脂联素在冠心病中的重要作用[J].心血管病防治知识(下半月),2012,(7)：47-49.
[26]张勤军,陈明聪APN、CD62P、hs-CRP在冠心病病程发展中的作用[J].放射免疫学杂志,2011,24(5)：554-556.
[27]金静,彭道泉,龚浩等.血清脂肪细胞型脂肪酸结合蛋白及脂联素水平与冠心病的相关性[J].中华心血管病杂志,2010,38(8)：706-710.
[28]曹学敏,金道群,陈志强等.冠心病患者血清脂联素和高敏C-反应蛋白水平及相关性研究[J].河北医药,2011,33(14)：2154-2155.
[29]薛亚彬.冠心病伴胰岛素抵抗患者血清脂联素水平的研究[J].中国医药指南,2012,10(15)：542-542.
[30]姜文兵,赵玮,张东矗等.血清脂联素水平与冠心病严重程度的相关性分析[J].中国医师进修杂志,2011,34(22)：3-6.
[31]牛新艳.血清脂联素水平及踝臂指数与冠状动脉病变程度的相关性研究[J].实用心脑肺血管病杂志,2012,20(3)：422-423.
[32]林鸿.脂联素与冠状动脉粥样硬化性心脏病临床研究进展[J].医学综述,2012,18(3)：354-356.
[33]孙卫平,吴永全,李觉等.脉搏波传导速度与冠心病心功能不全的相关性[J].中华内科杂志,2008,47(5)：382-384.
[34]贾新未,魏盟,陆志刚等.脉搏波传导速度对冠心病的诊断价值[J].诊断学理论与实践,2006,5(4)：332-335.
[35]王彦隆,闫旭龙,王增帅等.脉搏波速度、颈动脉内中膜厚度对冠状动脉粥样硬化预测价值及联合应用的意义[J].临床心血管病杂志,2010,26(12)：952-954.
[36]陈然,黄红光,戴海鹰等.冠心病患者血清脂联素水平的检测及意义[J].中国医师杂志,2010,12(11)：1548-1550.
[37]梁文生,蒋卫红.急性冠状动脉综合征患者血清脂联素和踝臂指数的变化及其相关性的研究[J].中国心血管杂志,2011,16(3)：189-191.
[38]朱文磊.探讨脂联素与冠心病危险因素的关系[J].四川医学,2010,31(10)：1546-1549.
[39]黄祥征,潘超英.检测冠心病患者APN和hs-CRP水平的临床意义[J].右江民族医学院学报,2011,33(5)：626-627.
[40]刘健,李群芳,吴洁等.脂联素对冠心病患者的保护作用研究进展[J].中国医药指南,2011,09(24)：6,10.
[41]黄祥征,潘超英.血浆脂联素检测在冠心病患者中的临床应用价值[J].齐齐哈尔医学院学报,2011,32(10)：1620.
[42]Dridi S, Taouis M. Adiponectin and energy homeostasis:Consensus and controversy [J]. J Nutr Biochem,2009,20(11):831-839.
[43]Matatda M, Shimomura I'Sara M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis[J]. J Biol Chem.2002,277: 37487-37491.
[44]Yokota T Oritani KTakahashi I et al. Adiponectin,a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of maerophages[J]. Blood.2000,96:1723-1732.
[45]张晓云,魏芳婧,徐力等.APN MMP-9hs-CRP在冠心病老年患者中的表达及临床意义[J].内蒙古医学杂志,2011,43(5)：513-516.
[46]李金怀,韩斌,杨文东等.冠心病患者血清脂联素和P-选择素水平变化及其检测价值[J].临床医学,2011,31(4)：99-100.
[47]臧传欣,贾永平,吕吉元等.冠心病患者测定血清脂联素的临床意义及相关性研究[J].中西医结合心脑血管病杂志,2010,8(4)：403-404.
[48]王琳.冠心病患者血清脂联素及抵抗素变化的分析[J].中国实用医药,2012,07(8)：108-110.
[49]王彦青,张丽英,高铭枢等.急性冠脉综合征患者血浆脂联素水平分析[J].中西医结合心脑血管病杂志,2011,09(11)：1380.
[50]刘雅娟,武海亮,杨锐英等.脂联素与冠心病类型和心血管危险因素的关系[J].临床心血管病杂志,2010,26(1)：11-14.
[51]齐杰,韩清华,马锋等.PWV、ABI、IMT与冠心病冠脉狭窄程度的相关性分析[J].中西医结合心脑血管病杂志,2010,8(2)：161-162.
[52]牟春霞,安毅,魏梅等.血尿酸、PWV和ABI与冠心病的关系[J].青岛大学医学院学报,2010,46(4)：309-311.
[53]贾新未,魏盟,陆志刚等.主动脉脉搏波传导速度升高与冠心病发病的相关性[J].临床心血管病杂志,2007,23(12)：910-912.
[54]赵旭燕,刘惠亮,马春梅等.冠心病患者高敏C反应蛋白和脉搏波传导速度检测的意义[J].心血管康复医学杂志,2010,19(3)：239-241.
[55]朱淑贤,钱菊英,葛均波等.大动脉僵硬度与冠心病相关性研究[J].中华老年医学杂志,2007,26(1)：9-12.
[56]孙军昌,安毅.冠心病病人脉搏波传导速度和踝臂指数变化及意义[J].齐鲁医学杂志,2009,24(3)：251-252,255.
[57]王文忠,陈瑜容.血清脂联素水平、动脉脉搏波传导速度与冠心病的相关性研究[J].临床内科杂志,2012,29(10)：705-706.
[58]Brochu-Gaudreau K, Rehfeldt C, Blouin R, et al. Adiponectin action from head to toe[J]. Endocrine,2010,37(1):11-32.
[59]Ambrosi P, Oddoze C, Habib G. Plasma adiponectin:Risk factor or risk marker for arterial stiffness? [J]. Am J Cardiol,2009,104(5):742.
[60]Bik W, Baranowska B. Adiponectin-a predictor of higher mortality in cardiovascular disease or a factor contributing to longer life? [J]. Neuro Endocrinol Lett, 2009,30(2):180-184.
[61]马聪,刘惠亮,王晓辉等.大动脉弹性与冠状动脉病变严重程度关系探讨[J].中国误诊学杂志,2008,8(23)：5545-5547.
[62]孟晓敏,王鸿懿,喜杨等.内源分泌型高级糖基化终末产物受体与冠心病危险因素对动脉弹性的影响[J].中华老年心脑血管病杂志,2010,12(9)：813-816.
[63]李更新,杨玉恒,马秀华等.老年缺血性心脑血管疾病患者PWV及ABI的差异比较[J].中国老年学杂志,2010,30(21)：3078-3079.
[64]王延风,常志文,梁杰等.大动脉弹性与冠状动脉粥样硬化严重程度的关系[J].中国综合临床,2007,23(3)：195-197.
[65]白宏兴,李小平,武治东等.脉搏波传导速度和踝臂指数与冠心病的关系[J].陕西医学杂志,2009,38(11)：1483-1484.
[66]贾新未,魏盟,陆志刚等.脉搏波传导速度在冠心病诊断中的应用价值[J].临床心血管病杂志,2007,23(7)：513-515.
[67]杜娟,姜少燕,李健等.急性冠脉综合征患者血浆IL-17、hs-CRP及PWV的变化及意义[J].山东医药,2010,50(33)：49-50.
[68]范中杰,程康安,张抒扬等.冠心病患者脉搏波流速的研究[J].中国心血管病研究杂志,2006,4(10)：726-729.
[69]刘伯芹,安毅,曹广智等.血浆脂联素水平与冠脉病变及PWV、ABI的关系研究[J].心脑血管病防治,2009,9(1)：6-8.
[70]Feener EP,King GL. Vascular dysfunction in diabetes mellitus[J]. Lancet,1997; 350(suppl): S13-S19.
[71]Y Ouehi, K Terashita,T Nakamura,et al. Aortic pulse wave velocity in patients with coronary atherosclerosis-a comparison with coronary angiographie findings. Nippon Ronen Igakkai Zasshi, January 1,1991; 28(1):40-45.
[72]李佳月,赵玉生,侯允天等.脉搏波传导速度与冠状动脉病变严重程度的相关性：324例老年病例分析[J].中华老年多器官疾病杂志,2012,11(5)：360-363.
[73]拓胜军,白宏兴,梁延宏等.脉搏波传导速度与冠状动脉病变程度的相关性研究[J].心血管康复医学杂志,2010,19(4)：439-441.
[74]李厚荣,杜国伟,殷波等.208例脉搏波速度与冠状动脉粥样硬化的临床分析[J].医学综述,2012,18(3)：451-454.
[75]王彦江,高明明,张麟等.脉搏波速度与冠状动脉病变严重程度的相关性研究[J].首都医科大学学报,2010,31(6)：799-802.
[76]龚武田,李家富,罗廷福等.脉搏波速与冠状动脉炎症状态的关系研究[J].实用心脑肺血管病杂志,2011,19(11)：1840-1842.
[77]陆兆华.冠心病及其高危因素人群脉搏波传导速度监测研究[J].安徽医学,2012,33(3)：312-313.
[78]曾玉玲,刘婷.脉搏波传导速度对冠心病的预测价值研究[J].临床合理用药杂志,2012,05(3)：15.
[79]彭玲湘,范咏梅.冠心病患者脉搏波速和踝臂指数检测的临床意义探讨[J].中国民康医学,2011,23(14)：1723-1724.
[80]范文茂,徐新,胡秀莲等.冠心病患者脉搏波传导速度与血浆脑钠肽水平的相关性研究[J].中国现代药物应用,2010,04(16)：38-39.
[81]甘辉.脉搏波传导速度、踝臂指数、血尿酸对冠心病的预测价值[J].浙江临床医学,2012,14(2)：190-192.
[82]王小荣,孙彦琴,贾耀文等.大动脉功能测定与冠状动脉粥样硬化病变相关性分析[J].中国现代医生,2008,46(22)：66-67.
[83]于安忠,李智,高绍喜等.脉搏波传导速度与冠状动脉粥样硬化的相关性研究[J].山东医药,2009,49(9)：48-49.
[84]Ouchi N, Kihara S, Adta Y et al. Adiponectin, an adipocyte-derived plasma protein. Inhibits endothelial NF-KB signaling through a cAMP-dependent pathway[J]. Circulation,2000,102:1296.
[85]刘晓方.PWV和ABI的测定在冠状动脉粥样硬化检测中的应用[J].宁夏医学杂志,2007,29(4)：379-382.
[86]蔡凯愉,张维忠,邱惠丽等.影响动脉弹性功能的临床因素分析[J].中华心血管病杂志,2007,35(3)：234-237.
[87]张明华,叶平,骆雷鸣等.健康人不同部位脉搏波传导速度、反射波增强指数之间的相关性及影响因素[J].中华心血管病杂志,2010,38(11):998-1005.
[88]谭静,华琦,闻静等.高血压病患者脉搏波速度与心血管疾病危险因素[J].中华高血压杂 志,2007,15(10)：807-811.
[89]曾靖,程李涛,唐利军等.增强指数评估动脉僵硬度不如脉搏波速度敏感[J].中国动脉硬化杂志,2008,16(1)：43-46.
[90]曲娜,刘晓方,王淑霞.脉搏波速度与冠状动脉粥样硬化的关系[J].中国动脉硬化杂志,2007,15(3)：217-220.
[91]El Khatib N, Genieys S, Kazmierczak B, et al. Reaction-diffusion model of atherosclerosis development[J]. J Math Biol,2011.
[92]Badheka AO, Rathod AD, Bharadwaj AS, et al. Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease [J]. Angiology, 2011,62(6):473-479.
[93]Campbell DJ, Somaratne JB, Jenkins AJ, et al. Differences in myocardial structure and coronary microvasculature between men and women with coronary artery disease[J]. Hypertension,2011,57(2):186-192.
[94]Cote M, Cartier A, Reuwer AQ, et al. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the epic-norfolk prospective population study) [J]. Am J Cardiol,2011,108(3):367-373.
[95]Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease[J]. Heart,2004; 90(5):528-533
[96]冯笑梅,冀虎岗.冠心病患者血浆脂联素水平变化的探讨[J].江西医学检验,2006；24(5)：388-389.
[97]Vaiopoulos AG, Marinou K, Christodoulides C, et al. The role of adiponectin in human vascular physiology [J]. Int J Cardiol,2011.
[98]Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies[J]. Hypertension,1995,26:485-490.
[99]Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement[J]. Hypertens Res,2002,25:359-364.
[100]Hisayo yokoyama, Tetsuo Shoji, Eiji Kimoto, et al. Pulse Wave Velocity in Lower-Limb Arteries among Diabetic Patientes with Peripheral Arterial Disease. J Atheroscler Thromb.2003; 10:253-258
[101]Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ankle pulse wave velocity:all index of central arterial stiffness?[J]. J Hum Hypertens,2005,19:401-406
[102]王宏宇,张维忠,龚兰生,等.高血压合并动脉粥样硬化与大动脉缓冲功能的研究[J].中华心血管病杂志,2000,29：206-209.
[103]Blacher J,Asmar R,Djane S, et, al. Aortic pulse wave velocity fits a marker of cardiovascularrisk in hypertension patiens[J], Hypertension.1999; 33:1111-1117.
[104]Sutton-Tyrrel K,Newman A, Eleanor M, et al. Aortic sjiffness is associated with visceral adiposity in older adults enrolled in the study of Health,Agoing, and Body Composition[J]. Hypertension,2001; 38:429-433.
[105]郭兰燕,夏珂,程晋芳等.冠心病伴糖代谢异常患者血浆脂联素和Apelin的水平及临床意义[J].临床心血管病杂志,2011,27(10)：732-735.
[1]Yamaucki T,KamoN J, et al. globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis[J].Biol-Chem,2003,278:2461-2468.
[2]Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C 1 q, produced exclusively in akipocytes[J].Biol Chem,1995,270(45):26746-26749.
[3]张静,牛凡.血清瘦素、脂联素与冠心病病变程度的相关性研究[J].中西医结合心脑血管病杂志,2012,10(7)：783-784.
[4]王文忠,陈瑜容.血清脂联素水平、动脉脉搏波传导速度与冠心病的相关性研究[J].临床内科杂志,2012,29(10)：705-706.
[5]邓琳,李树壮.脂联素对冠心病的保护作用及其机制[J].大连医科大学学报,2012,34(3)：297-300.
[6]盛延文,王玉梅,梁菊萍等.冠状动脉粥样硬化病变患者血清脂联素的表达及临床价值[J].中国老年学杂志,2011,31(17)：3272-3273.
[7]Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity [J]. Nat Med,2001,7(8):941-946.
[8]Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects [J]. Nature,2003,423(6941):762-769.
[9]熊鹏锋,涂燕平.脉搏波传导速度与冠心病关系的研究进展[J].中国老年学杂志,2011,31(12)：2380-2382.
[10]陈希伟,韦建瑞,罗景云等.脉搏波传导速度在心血管病的应用进展[J].国际医药卫生导报,2011,17(7)：888-891.
[11]Guo XH, Wu LL, Li L. [progress in signal pathways involved in glucose and lipid metabolism induced by adiponectin] [J]. Sheng Li Ke Xue Jin Zhan,2010,41(6):471-474.
[12]Chinetfi G Zawadski C, Fmchart JC, et al. Expression of adiponectin receptors in human macrophages and regulation by agonists ofthe nuclear receptors PPAR alpha, PPAR gamma,and LXR[J]. Biochem Biophys Res Commun,2004,314:151.
[13]郝燕婷,张永珍,毛节明等.脉搏波速度与冠状动脉血流速度储备的相关性[J].中华医学杂志,2012,92(10)：685-688.
[14]耿国英,李凌,韩文杰等.冠心病合并糖尿病患者脉搏波传导速度的变化[J].中国医药指南,2012,10(2)：22-24.
[15]孙洪勇,黄健,李莉等.高血压病合并冠心病与大动脉脉搏波速度的关系[J].贵阳医学院学报,2008,33(4)：392-393.
[16]Hattori Y.Suzuki M.Hattori S, et al. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells[J].Diabetologia.2003,46(5):1543-1549.
[17]Chen H.Montagnani M.Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells [J]. JBiol Chem.2003,278(7):45021-45026.
[18]Ouchi N.Kihara S.Funahasi T, et al.Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.Circulation,2003,107(3):671-674.
[19]Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin act as an endogenous antithrombotic factor[J]. Arterioscl Thromb Vasc Biol,2006,26(1):224-230.
[20]韩文杰,刘恒亮,刘洋等.短期降糖治疗对冠心病并糖尿病患者脉搏波传导速度的影响[J].河南医学研究,2012,21(3)：299-301.
[21]刘晓芳,黄建英,张胜利等.冠心病患者血清脂联素水平与高敏C反应蛋白和胰岛素抵抗的关系[J].国际检验医学杂志,2013,34(2)：149-150.
[22]卢世明,刘占英,孙爱叶等.2型糖尿病合并冠心病患者脂联素测定及其意义[J].中国医学创新,2011,08(25)：5-8.
[23]黄祥征,潘超英.血浆脂联素检测在冠心病患者中的临床应用价值[J].齐齐哈尔医学院学报,2011,32(10)：1620.
[24]Maeda N.Shimomura l.Kishida K,el al. Diet-induced insulin resistance in micelaclcing adiponectin/ACRP30[J].Nat Med,2002,8(5):2654-2660.
[25]Julius S. Kjeldsen SE.Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial[J].Lancet.2004,363:2022-2031
[26]Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women[J]. Eur J Endoerinol,2002, 147:173-180.
[27]蔡静,李洁琪.不同病因房颤患者血浆脂联素与B型利钠肽前体及心功能的关系[J].山东医药,2012,52(37)：17-19.
[28]张宁汝,张恒,王本芳等.脂联素与冠心病临床相关性研究[J].中华全科医学,2012,10(5)：688-689.
[29]张宁汝,李妙男,张恒等.APN与冠脉病变程度相关性研究[J].中华全科医学,2012,10(8)：1194-1196.
[30]潘桂林,XU Da-hua,高潮等.脂联素：心血管疾病新的危险预测因子[J].心血管病学进展,2008,29(4)：628-632.
[31]王彦青,张丽英,高铭枢等.急性冠脉综合征患者血浆脂联素水平分析[J].中西医结合心脑血管病杂志,2011,09(11)：1380.
[32]Hotta K, Funahashi T, Bodkin NL, et al. Circulating concent rations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys[J]. Diabetes,2001,50(5):1126.
[33]Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal for mation[J]. J Biol Chem,2002,227(29):25863.
[34]雷娟,周淑娴,薛声能等.血清脂联素水平与冠脉病变严重程度的关系[J].中国医师杂志,2008,10(2)：195-197.
[35]耿银东,牟春平,赵晓辉等.脂联素和糖化血红蛋白与冠脉病变程度的相关性[J].心血管康复医学杂志,2010,19(2)：140-143.
[36]刘伯芹,安毅,曹广智等.血浆脂联素水平与冠脉病变及ABI的关系研究[J].心脑 血管病防治,2009,9(1)：6-8.
[37]Maeda N, Takahashi M, Funahashi T, et al. PPAR γ ligands increase express and plasma concentrations of adiponeetill, an adipose-derived protein[J]. Diabetes,2001,50:2094.
[38]Yu J GJavorschi S, Hevener AL, et al. The effect ofthiazolidinedione on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects[J]. Diabetes,2002, 51:2968-2974.
[39]李小平,杨成悌,张灵,等.高血压病患者血清脂联素水平的研究[J].中华心血管病杂志,2004,32(7)：596-599.
[40]邵明柏,冷吉燕,崔倩卫.老年高血压伴肥胖患者血清脂联素水平的变化及其临床意义[J].中国老年学杂志,2010,30(18)：2582-2584.
[41]周淑娴,雷娟,张玉玲,等.高血压患者胰岛素抵抗与血清脂联素及炎症标志物水平[J].中华高血压杂志,2008,16(2)：166-170.
[42]Admaczak M, Wiecek A, FullahaShi T, et al, challges plasma adiponectin concentration In patients with essentid hypertens[J], Am J HyperteIns,2003,16(1):72
[43]furuhashi M, Ura N, Higashiura K, et al, Blockade ofthe reInin angiotensin system increases adiponectin concertration in patients with essential hypertension[J], Hypertensio 2003.42:76-81.
[44]Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin:more than just another fat cell hormone?[J].Diabetes Care,2003,26(8):2442-2450.
[45]焦路阳,袁彬,袁晓梅等.血清内脂素、脂联素和C-反应蛋白与冠状动脉病变的相关性[J].新乡医学院学报,2012,29(8)：600-602.
[46]牛新艳.血清脂联素、血清淀粉样蛋白A与冠状动脉病变的相关性研究[J].中国全科医学,2011,14(28)：3232-3234.
[47]Fruebis j, Tsao TS, Javorschi S, et al.Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in Hlusele and caoses weight loss in mice[J]. Proc Natl Acad Sci USA,2001,98(4):2005-2010.
[48]Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis[J]. J Biol Chem,2002,277:37487
[49]刘蕴玲,阴东亮,刘好田,等.肥胖儿童血清脂联素水平与代谢综合征、早期动脉粥样硬化的相关性研究[J].中华内分泌代谢杂志,2010,26(9)：749-753.
[50]李筱雯,艾华,张宝慧,等.肥胖者或超重者血脂联素和心血管危险因素在减体重后的变化[J].中国康复医学杂志,2006,21(2)：132-135.
[51]Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. NatMed,2002,8(7):731.737.
[52]Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk [J]. Curr Med Chem,2010,17(36):4511-4520.
[53]Dagli N, Ozturk U, Karaca I, et al. Adiponectin levels in coronary artery ectasia [J]. Heart Vessels,2009,24(2):84-89.
[54]魏红霞,张葵,李雷等.血清脂联素与载脂蛋白A5及2型糖尿病的关系[J].现代生物医学进展,2012,12(8)：1498-1501.
[55]李晓燕,王铁成,刘世雷等.血清脂联素水平与冠状动脉病变程度的关系[J].中国血液流变学杂志,2009,19(3)：387-389.
[56]束振华.血清vWF及APN的检测与冠心病的关系及其临床意义[J].现代诊断与治疗,2011,22(3)：129-131.
[57].Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis and thrombosis [J]. Clin Appl Thromb Hemost,2006,12(2):163-168.
[58]Nalcamura Y,Shimada K,Fukuda D, et al.Implications of plasma con2centrations of adiponectin in patients with coronary artery disease [J].Heart (British Cardiac Society),2004,90 (5):528-533.
[59]杨金凤.血清脂联素对冠心病冠状动脉病变评估的价值[J].浙江临床医学,2012,14(6)：729-730.
[60]李晓红,卢伟智,刘怀昌等.代谢综合征对冠心病患者脂类代谢及炎症因子的影响[J].海南医学,2010,21(14)：53-54,67.
[61]张勤军,陈明聪.APN. CD62P, hs-CRP在冠心病病程发展中的作用[J].放射免疫学杂志,2011,24(5)：554-556.
[62]宋高峰,杨文东.2型糖尿病合并冠心病与脂联素及炎性因子的相关性[J].航空航天医学杂志,2011,22(8)：961-962.
[63]Kumada M,Kihara S,Ouchi N, et al.Adiponectin specifically increasedtissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macropages[J]Circulation 2004,109(17):2046-2049.
[64]Iacobellis G, Pistilli D, Gucciardo M, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease [J]. Cytokine, 2005,29(6):251-255.
[65]牛新艳.血清脂联素水平及踝臂指数与冠状动脉病变程度的相关性研究[J].实用心脑肺血管病杂志,2012,20(3)：422-423.
[66]李金怀,韩斌,杨文东等.冠心病患者血清脂联素和P-选择素水平变化及其检测价值[J].临床医学,2011,31(4)：99-100.
[67]王小凤,王毅,杨建国等.血清脂联素水平与高血压肥胖患者胰岛素抵抗的关系[J].中国老年学杂志,2013,33(1)：183-185.
[68]Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk [J]. Curr Med Chem,2010,17(36):4511-4520.
[69]Kobalava Zh D, Villeval'de SV, Isikova Kh V. [the role of adiponectin in development and progression of cardiovascular diseases] [J]. Kardiologiia,2009,49(1):51-58.
[70]Koz C, Uzun M, Yokusoglu M, et al. Evaluation of plasma adiponectin levels in young men with coronary artery disease [J]. Acta Cardiol,2007,62(3):239-243.
[71]Kizer JR, Benkeser D, Arnold AM, et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults [J]. J Clin Endocrinol Metab, 2013,98(1):255-263.
[72]Kanhai DA, Kranendonk ME, Uiterwaal CS, et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies [J]. Obes Rev, 2013.
[73]Zhang BC, Li WM, Xu YW. A meta-analysis of the association of adiponectin gene polymorphisms with coronary heart disease in chinese han population [J]. Clin Endocrinol (Oxf),2012,76(3):358-364.
[74]Xia K, Guo L, Zhao Z, et al. [plasma level of adiponectin in coronary heart disease patients combined with abnormal glucose metabolism] [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2012,37(2):179-184.
[75]EI-Mesallamy HO, Hamdy NM, Salman TM, et al. Adiponectin and se-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease [J]. Angiology,2012,63(2):96-102.
[76]Baldasseroni S, Mannucci E, Orso F, et al. Adiponectin in outpatients with coronary artery disease:Independent predictors and relationship with heart failure [J]. Nutr Metab Cardiovasc Dis,2012,22(3):292-299.
[77]Zhou NN, Zhuo JM, Wang JC, et al. [correlation of adiponectin gene snp+45t/g polymorphism and premature coronary heart disease of han ethnic males] [J]. Zhonghua Yi Xue Za Zhi, 2011,91(48):3413-3416.
[78]Prior SL, Jones DA, Gill GV, et al. Association of the adiponectin rs266729 c>g variant and coronary heart disease in the low risk'golden years'type 1 diabetes cohort [J]. Diabetes Res Clin Pract,2011,91(3):e71-74.
[79]Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women [J]. Atherosclerosis,2011,219(1):322-329.
[80]Parul SS, Mazumder M, Debnath BC, et al. Serum adiponectin in patients with coronary heart disease [J]. Mymensingh Med J,2011,20(1):78-82.